Role of angiotensin-converting-enzyme inhibition in patients with renal disease

American Journal of Health-System Pharmacy

Volumn 57, Issue 19 SUPPL. 1, 2000, Pages

  Manley, H J ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

Angiotensin converting enzyme inhibitors; Clinical studies; Kidney diseases; Kidney failure

Indexed keywords

CAPTOPRIL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LISINOPRIL; PLACEBO; RAMIPRIL;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG ACTIVITY; DRUG EFFECT; HIGH RISK PATIENT; HUMAN; HYPERTENSION; KIDNEY BLOOD FLOW; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; LONG TERM CARE; MICROALBUMINURIA; PRIORITY JOURNAL;

EID: 0034307334     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/57.suppl_1.s12     Document Type: Conference Paper

References (23)

1. Angiotensin converting enzyme inhibitors in nondiabetic renal disease
2. Effect of angiotensin converting enzyme inhibition by perindopril on proteinuria of primary renal diseases
3. Randomized trial of captopril for microalbuminuria in normotensive adults with sickle cell. Anemia
4. Captopril and renal survival in patients with human immunodeficiency virus nephropathy
5. Low dose angiotensin converting enzyme inhibition and glomerular permselectivity in renal transplant recipients
6. Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): A position paper of the National Kidney Foundation
7. Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy
8. The role of angiotensin II in diabetic nephropathy-emphasis on nonhemodynamic mechanisms
9. Effects of antihypertensive therapy on progression of diabetic nephropathy
10. Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria
11. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
12. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria
13. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients
14. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus
15. Vitamin E supplementation and cardiovascular events in high-risk patients
16. Effects of ramipril on cardiovascular and microvascular outcomes in pe6ple with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy
17. Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies
18. Dissociation between the course of [he hemodynamic and antiproteinuric effects of angiotensin I converting enzyme inhibition
19. Long-term effects of antihypertensive agents on proteinuria and renal function
20. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy
21. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria
22. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial